The only effective method for treating acute myocardial infarction is restoration of coronary perfusion in the basin of the infarct-associated coronary artery [5, 8, 10] . Without recanalization of this artery, the size of the myocardial infarct cannot be limited. Unfortunately, ischemic and reperfusion injuries to the heart develop very quickly. Thus, data obtained in our laboratory show that extensive necrotic plaques in rats appear after 20-min coronary occlusion and 3-h reperfusion [9] . In this situation, it is important to win time and prevent the development of irreversible cardiomyocyte damage before circulation is restored, so pharmacological and non-medication-based treatments directed to increasing the tolerance of the heart to ischemia/reperfusion would be of inestimable value.
The only effective method for treating acute myocardial infarction is restoration of coronary perfusion in the basin of the infarct-associated coronary artery [5, 8, 10] . Without recanalization of this artery, the size of the myocardial infarct cannot be limited. Unfortunately, ischemic and reperfusion injuries to the heart develop very quickly. Thus, data obtained in our laboratory show that extensive necrotic plaques in rats appear after 20-min coronary occlusion and 3-h reperfusion [9] . In this situation, it is important to win time and prevent the development of irreversible cardiomyocyte damage before circulation is restored, so pharmacological and non-medication-based treatments directed to increasing the tolerance of the heart to ischemia/reperfusion would be of inestimable value.
One such treatment, discovered in 1986 by Murry et al. [24] , is the phenomenon termed "ischemic preconditioning" (IP). The essence of this phenomenon is that after 1-3 sessions of transient ischemia and reperfusion, the myocardium becomes more resistant to the effects of prolonged ischemia and reperfusion [24] . The cardioprotective effect of IP persists for about 3 h in experimental conditions [7, 31] .
This preconditioning is termed "early" or "classical." The "gold standard" for preconditioning is a decrease in the infarct zone/risk zone ratio (IZ/RZ). The risk zone is termed the ischemic zone. Unfortunately, preconditioning provokes ventricular arrhythmias [22, 24] , so much attention is currently being paid to seeking pharmacological agents mimicking the phenomenon of IP but not evoking impairments to cardiac rhythm [6] . Our previous data [1] indicate that the cannabinoid (CB) receptor agonist HU-210 [(6-ar)-trans-3-(dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-bicenzo[b,d]pyran-9-methanol] may be such a compound. We have suggested that mimicking the phenomenon of IP by HU-210 occurs as a result of stimulation of CB receptors and increases in the activity of protein kinase C and NO synthase, which are components in the signal mechanism involved in preconditioning [7, 31] .
The aim of the present work was to study the role of cannabinoid receptors, protein kinase C, and NO synthase in the mechanism of HU-210-induced increases in the resistance of the heart to ischemia and reperfusion.
Methods
In vivo experiments were performed on male Wistar rats weighing 250-300 g under anesthesia with i.p. α-chloralose (50 mg/kg). Animals were ventilated mechanically with a modifi ed RO-6 apparatus (Krasnogvardeets, St. Pet-er sburg, Russia). The right carotid artery was cannulated to measure arterial blood pressure (BP), which was recorded with an SS13L pressure probe (Biopac System Inc., Goleta, California, USA) connected to an MP35 electrophysiological study system (Biopac System Inc., Goleta, USA). This same apparatus was used for ECG recordings. Data were analyzed quantitatively in INSTBSL-W (Biopac System Inc., Goleta, USA).
Coronary occlusion (45 min) and reperfusion (2 h) were produced using a technique described previously by Schulz et al. [27] . Infarct plaque sizes were measured as described by Schulz et al. [27] . After each experiment, the left coronary artery was reoccluded and animals received i.v. 10% Patent blue violet solution at a dose of 40 mg/kg to stain areas of the left ventricle with normal blood fl ow. Rats were sacrifi ced by injection with 15% KCl solution. Hearts were excised and the left ventricle was harvested; six cross sections of thickness about 1 mm were prepared. This procedure allowed visualization of the nonischemic area and the risk zone. The risk zone was separated from intact myocardium. This zone was incubated for 15 min with 0.1% nitroblue tetrazolium (NBT) in 100 mM phosphate buffer pH 7.4 at 37°C. NBT stain identifi es viable and nonviable tissues. It is rapidly reduced by dehydrogenases present in living myocardium, so tissue stains a silver color. As nonviable infarcted myocardium lacks dehydrogenases, the tissue retains is pale pink color. The IZ and RZ of the of the infarct zone were evaluated gravimetrically. The IZ was then expressed as a percentage in relation to the RZ (IZ/RZ) and as a percentage of left ventricle weight (IZ/LV). The ECG was recorded during 45 min of ischemia and the fi rst 10 min of reperfusion.
Studies used the CB1 and CB2 receptor agonist HU-210 [25] , which was given i.v. at a dose of 0.1 mg/kg 15 min before coronary occlusion. The dose was selected on the basis of our previously published data [1] . The CB1 receptor antagonist SR141716A (N-[piperidin-1-yl]-1-[1,2-dichlo rophe nyl]4-methyl-1H-pyrazole-3-carboxamide HCl) was given i.v. at a dose of 1 mg/kg 25 min before coronary occlusion [13, 21] . The CB2 receptor antagonist SR144528 (N-(1S)-endo-1,3,3-trimethylbicyclo[2,2,1]hepta-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl))pyraxole-3-carboxamde) was given i.v. at a dose of 1 mg/kg 25 min before coronary occlusion [18] . The protein kinase C (PKC) inhibitor chelerythrine was used at a dose of 5 mg per 1 kg 25 min before coronary occlusion [17] . The NO synthase inhibitor L-NAME (N G -nitro-L-arginine methyl ester) was given i.v. at a dose of 10 mg/kg 25 min before coronary oc clusion [15] .
Chelerythrine is poorly soluble in water at room temperature, so it was dissolved in warm (+55°C) physiological saline and the solution was then cooled to +37°C. Cannabinoid HU-210, SR141716A, and SR144528 were dissolved in a mixture of Cremaphor EL/ethanol/0.9% NaCl solution (1:1:18) [30] . L-NAME was dissolved in physiological saline. All solutions were prepared immediately before use.
In vitro experiments were performed on isolated hearts from male Wistar rats weighing 250-300 g under ethyl ether anesthesia. After extraction of hearts from the chest cage, they were rapidly transferred to a bath containing Krebs-Hanseleit solution cooled to +4°C until termination of spontaneous contractions. A cannula was then inserted into the ascending aorta for retrograde perfusion of the heart with Krebs-Hanseleit solution by the Langendorff method. Oxy genated perfusion solution (37°C, pH 7.4) containing 120 mM NaCl, 4.8 mm KCl, 2.0 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 20.0 mM NaHCO 3 , and 10 mM glucose was prepared using reagents from MP Biomedicals, Irwin USA. Krebs-Hanseleit solution was prepared with distilled water additionally purifi ed on Millipore Simplicity apparatus (USA).
Levels of necrotic injury to cardiomyocytes were assessed in terms of the level of creatine phosphokinase (CPK) in the perfusate fl owing from hearts. CPK activity was measured using a Smart Spec Plus spectrophotometer from Bio-Rad (USA) using a CK-NAc enzyme kit from Analiticon Biotechnologies (Lichtenfeis, Germany). Final results were expressed as μmol NADH/min per 1 g myocardial tissue. Cardiac contractility parameters in the cavity of the left ventricle were measured by introducing a catheter with a latex balloon fi lled with distilled water, using a sufficient volume to create an end diastolic pressure of 10-15 mmHg. Cardiac pump function was evaluated with an SS13L pressure probe (Biopac System Inc., Goleta, Cali fornia, USA) connected to the balloon. Heart rate (HR, bpm) was recorded during the experiment, along with the pressure developed by the left ventricle (mmHg). The latter was determined as the difference between the systolic and diastolic pressures. Measurements of end diastolic pressure (EDP, mmHg) were made during the experiment.
The agents used in these studies were dissolved in dimethylsulfoxide. The exception was L-NAME, which was dissolved in Krebs-Hanseleit solution. The fi nal dimethylsulfoxide concentration was 0.01%. Our preliminary experiments showed that dimethylsulfoxide at this concentration has no effect on HR, myocardial contractility, or cardiac resistance to ischemia and reperfusion. The CB1 and CB2 receptor agonist HU-210 was used [25] . The CB agonist concentrations (0.1 and 1.0 μM) were selected on the basis of our previous data on the cardioprotective activity of HU-210 [3] . The roles of CB1 and CB2 receptors in mediating the car dioprotective effects of cannabinoids were studied using the selective CB1 receptor antagonist SR141716A at a fi nal concentration of 0.1 μM [2] and the selective CB2 receptor antagonist SR144528 at a fi nal concentration of 0.1 μM [2] . The roles of signal systems were studied using the following pharmacological agents: the protein kinase C (PKC) inhibitor chelerythrine (2 μM) [12] and the NO synthase inhi bitor L-NAME at a concentration of 100 μM [11] . The experimental scheme is shown in Fig. 1 . This shows that perfusion of hearts with solution containing HU-210 was continued for 10 min and was followed by perfusion without agent for 10 min, after which ischemia was induced (45 min) followed by reperfusion (30 min) . This experimental protocol is regarded as a model of ischemic preconditioning [31] .
Cannabinoid HU-210 was from Tocris Bioscience (Bri s tol, UK); cremaphore EL, L-NAME, Patent blue violet, dimethylsulfoxide, and nitroblue tetrazolium were from Sigma-Aldrich (USA); chelerythrine was from LC Laboratories Company (USA). CB receptor antagonists were kindly provided by Dr. F. Barth, Sanofi -Aventis (France). Data were analyzed in Statistica 6.0. Signifi cant differences were identifi ed using the Mann-Whitney test. Differences were regarded as statistically signifi cant at p < 0.05. The results of all experiments are presented as M ± m, where M is the arithmetic mean and m is the standard error of the mean; n is group size.
Results As shown in Fig. 2 , coronary occlusion and subsequent reperfusion in vivo induced the formation of an infarct plaque amounting to 58% of the size of the risk zone (control group). Prior i.v. administration of HU-210 (0.1 mg/kg) led to a signifi cant decrease in the IZ/RZ index, by a factor of 1.5. During ischemia, there were decreases in systolic and mean arterial blood pressure (BP) by 10 mmHg. Ventricular arrhythmias (multiple ventricular extrasystoles, ventricular tachycardia, and ventricular fi brillation) were seen in 90% of rats during coronary occlusion. Only multiple ventricular extrasystoles were recorded during reperfusion, in 7% of individuals (data not shown). There were no changes in BP or the incidence of arrhythmias after use of HU-210 as compared with controls (data not shown).
The selective CB1 receptor antagonist SR141716 completely blocked the infarct-limiting effect of HU-210 (Fig. 2) , while the selective CB2 receptor antagonist SR144528 had no such action. These cannabinoid receptor antagonists given alone did not affect the IZ/RZ ratio.
Our further in vivo studies addressed the intracellular signal mechanisms of the infarct-limiting action of HU-210. As shown in Fig. 3 , the PKC inhibitor chelerythrine eliminated the cardioprotective effect of HU-210, while administration of the NO synthase inhibitor L-NAME had no effect on the HU-210-induced increase in cardiac resistance to ischemia and reperfusion. Injections of chelerythrine alone or L-NAME alone had no effect on the IZ/RZ index.
Our in vitro experiments established that CPK activity in perfusate coming from hearts increased 4.5-fold after global ischemia for 45 min as compared with baseline (Fig. 4) , which is evidence of cardiomyocyte necrosis. Cardiac perfusion with Krebs-Hanseleit solution containing 0.1 μM HU-210 for 10 min decreased CPK release from the myocar dium during reperfusion by a factor of 2. These data provide evidence that HU-210 has an antinecrotic action. An increase in the HU-210 concentration to 1 μM did not incre ase the cytoprotective effect of the CB agonist used here (Fig. 4) .
Experiments on isolated perfused hearts showed that ischemia/reperfusion decreased HR from 202 ± 12 to 152 ± 11 bpm at 5 min of reperfusion (p < 0.01). Use of 0.1 μM HU-210 exacerbated reperfusion bradycardia, decreasing HR at 5 min of reperfusion to 98 ± 11 bpm (p < 0.01 compared with controls). An increase in the HU-210 concentration to 1 μM did not increase cannabinoid-induced bradycardia.
Ischemia-reperfusion decreased myocardial contractility, as evidenced by a decrease in the pressure developed by the left ventricle, from 60 ± 9 mmHg at baseline to 41 ± 9 mmHg at 5 min of reperfusion. Use of cannabinoid HU-210 had no effect on left ventricular contraction strength, which was decreased during reperfusion.
Reperfusion (5 min) increased EDP by 75% of pre-ischemia baseline (p < 0.01). Cannabinoid HU-210 at a concentration of 0.1 μM had no effect on the reperfusion-induced increase in EDP, while HU-210 at 1 μM almost completely eliminated the increase in EDP during reperfusion. The difference between the controls and the HU-210 group was signifi cant (p < 0.01). Fig. 3 . Effects of the cannabinoid receptor agonist HU-210 (0.1 mg/kg), the NO synthase inhibitor L-NAME, and the NO synthase inhibitor chelerythrine on the percentage ratio of the necrosis zone to the risk zone in an experimental model of myocardial infarct (45 min ischemia followed by 120-min reperfusion). *Signifi cant difference compared with control group, p < 0.01.
Mimicking the Phenomenon of Ischemic Preconditioning
Cannabinoid HU-210 at concentrations of 0.1 and 1.0 μM had no effect on the incidence of reperfusion arrhythmias (data not shown).
On the basis of these data, further experiments used HU-210 at a condition of 0.1 μM.
Using CB receptor antagonists, we sought to explain the receptor nature of the cardioprotective effect of HU-210. Selective blockade of CB1 receptors with SR141716 was found to produce complete elimination of the cytoprotective action of HU-210 (Fig. 5) , while the CB2 receptor antagonist SR144528 had no infl uence on the protective effect of this cannabinoid. The use of antagonists alone had no effect on reperfusion-induced myocardial CPK release.
Addition of the PKC inhibitor chelerythrine to the perfusion solution before modeling of ischemia completely prevented the cardioprotective effect of HU-210 (Fig. 6) . Addition of the NO synthase inhibitor L-NAME to the perfusion solution did not prevent the HU-210-induced increase in the tolerance of the heart to ischemia/reperfusion (Fig. 6) . Addition of L-NAME or chelerythrine alone had no effect on outfl owing perfusate CPK levels.
Discussion
The results of the in vivo experiments reported here provide convincing evidence that the infarct-limiting action of HU-210 is mediated by activation of CB1 receptors, as the selective antagonist of these receptors SR141716 com- Fig. 4 . Effects of HU-210 at concentrations of 0.1 and 1.0 μM on creatine phosphokinase activity in the perfusion solution before and during reperfusion. Signifi cant differences compared with controls, *p < 0.05; signifi cant differences compared with baseline, # p < 0.05, ## p < 0.01. Fig. 5 . Perfusate CPK levels during reperfusion in series with the CB1 and CB2 receptor agonist HU-210 (0.1 μM), the CB1 receptor antagonist SR141716 (0.1 μM), and the CB2 receptor antagonist SR144528 (0.1 μM). Signifi cant differences compared with controls, *p < 0.05. pletely blocked this effect. There are grounds supporting the view that endogenous cannabinoids in nonadapted animals are not involved in regulating the tolerance of the heart to the actions of ischemia/reperfusion, as CB receptor antagonists used alone had no effect on the IZ/RZ ratio. The key role in the mechanism of the cardioprotective effect of HU-210 is played by protein kinase C. The disappearance of the infarct-limiting effect of HU-210 after use of the PKC inhibitor chelerythrine can be regarded as an argument supporting this view. This observation is consistent with the widely held view that PKC plays an important role in the mechanisms of ischemic preconditioning and that the cardioprotective effects of substances mimicking this phenomenon are also linked with activation of protein kinase C [6, 7, 31] . Our recent literature review contains a detailed exposition of data showing that apart from "classical" IP, there is also delayed preconditioning [4] . The essence of this phenomenon is that 24 h after a transient session of coronary occlusion there is a repeat increase in the tolerance of the heart to ischemia and reperfusion [4] . The key role in mediating delayed IP is played by NO synthase [4] , as NO synthase inhibitors completely block the infarct-limiting effect of delayed preconditioning. However, this enzyme does not have a role in the mechanisms of the cardioprotective effect of early IP [23] . Results obtained from the in vivo experiments reported here indicate that the infarct-limiting effect of HU-210 is independent of activation of NO synthase. This suggests that the use of this cannabinoid can be used to mimic the phenomenon of classical preconditioning.
Our experiments on isolated perfused hearts showed that the cardioprotective effect of HU-210 is due to activation of cardiac CB1 receptors, as this effect was not apparent on the background of selective blockade of these receptors. However, the results of the present studies, reported above, show that endogenous cannabinoids are not involved in regulating the resistance of the isolated heart to the pathogenic actions of ischemia/reperfusion in nonadapted individuals.
As in in vivo experiments, inhibition of PKC by chelerythrine eliminated the HU-210-induced increase in the tolerance of isolated hearts to ischemia/reperfusion. The NO synthase inhibitor L-NAME had no effect on the cardioprotective effect of HU-210. This suggests that NO synthase, unlike PKC, does not have a role in mediating the cardioprotective effect of HU-210.
Our results are consistent with data from other studies, showing analogous cardioprotective effects with cannabinoid receptor agonists [14, 20, 28, 29] . The question of the receptor nature of this effect of cannabinoids remains controversial. Some investigators take the view that the cardioprotective effects of CB receptor agonists are linked with activation of anandamide receptors [29] , which are distinct from CB1 or CB2 receptors. Others believe that the infarct-limiting action of cannabinoids is associated with activation of CB2 receptors [14, 28] . A third group has postulated [20] that the increase in the tolerance of the heart to the actions of ischemia/reperfusion may occur as a result of stimulation of both CB1 and CB2 receptors. Our data suggest that regulation of the resistance of the heart to ischemia/reperfusion involves only CB1 receptors. The reason for the contradictions in assessments of the receptor nature of the cardioprotective action of cannabinoids remains unclear. It is entirely possible that it arises from the fact that different authors use different CB receptor agonists.
Our analysis of publications addressing intracellular signaling of the cardioprotective action of cannabinoids identifi ed only one article whose authors noted that the cardioprotective effect of the cannabinoid palmitoylethanolamine is linked with activation of PKC [19] . This is consistent with our results. In addition, it should be noted that palmitoylethanolamine is an agonist of cannabinoid GPR55 Fig. 6 . Perfusate CPK levels during reperfusion in series with the CB1 and CB2 receptor agonist HU-210 (0.1 μM), the protein kinase C inhibitor chelerythrine (5 mg/kg) and the NO synthase inhibitor L-NAME (10 mg/kg). Signifi cant differences compared with controls, *p < 0.05. receptors and CB2 receptors, and does not interact with CB1 receptors [16, 26] . Thus, there are weighty grounds for suggesting that the protective effect of palmitoylethanolamine is associated with activation of GPR55 or CB2 receptors, while the cardioprotective action of HU-210 results from occupation of CB1 receptors. The key role in the mechanism mediating the infarct-limiting actions of both cannabinoids is probably played by PKC.
In 2007, a Canadian group reported [20] results from their experiments on isolated perfused rat hearts. These experiments involved 90-min low-fl ow ischemia, decreasing coronary fl ow to 0.6 ml/min, followed by 30-min reperfusion. Pharmacological agents were added to the perfusate 5 min before ischemia and perfusion was continued with agents throughout the ischemia period and terminated at the moment at which reperfusion was reinitiated, i.e., the total duration of action of pharmacological agents was 95 min [20] . Their data indicated that the IZ/RZ ratio was decreased by the selective CB1 receptor agonist ACEA (arachidonyl-2-chloroethylamide) and the selective CB2 receptor agonist JWH015 (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethadone) [19, 20] . The infarct-limiting effect of ACEA was not apparent in conditions of blockade of NO synthase with L-NAME, while the cardioprotective effect of JWH015 persisted in these conditions [20] . At fi rst sight, these data are contradicted by the results of our studies, which indicate that NO synthase does not take part in the infarct-limiting action of HU-210. However, attention should be paid to the fact that the duration of action of HU-210 in our studies was 10 min, while the duration of cardiac perfusion with cannabinoid-containing solution in the Canadian studies was 95 min. It can be suggested that cannabinoid-induced activation of NO synthase in cardiomyocytes occurs only on prolonged stimulation of CB1 receptors.
Thus, our results provide evidence that stimulation of CB1 receptors constitutes a variant of the pharmacological mimicking of the phenomenon of preconditioning. As the cardioprotective effects of cannabinoid HU-210 are seen in both in vivo and in vitro experiments, there are grounds for suggesting that the protective effects of HU-210 is mediated by activation of cardiac CB1 receptors. These data indicate that the cardioprotective effect of cannabinoid HU-210 are associated with stimulation of protein kinase C, while NO synthase is not involved in the protective action of stimulation of CB1 receptors.
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